News Gan & Lee Pharmaceuticals.

Equities

603087

CNE100003ZH1

Pharmaceuticals

End-of-day quote Shanghai S.E. Other stock markets 07/05/2026			5-day change	1st Jan Change
59.98 ^CNY	+1.39%		+1.92%	-11.88%

05-07	Gan & Lee Pharmaceuticals Gets Nod to Market Dazparda in Europe	MT
04-22	Gan & Lee Pharmaceuticals 2025 net profit up 86.1% y/y	RE

All News

Mentions Relevance

05-07	Gan & Lee Pharmaceuticals Gets Nod to Market Dazparda in Europe	MT
04-22	Gan & Lee Pharmaceuticals 2025 net profit up 86.1% y/y	RE
04-22	Gan & Lee Pharmaceuticals. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
04-16	Gan & Lee Pharmaceuticals Gets Nod to Trial GLR1062 Injection	MT
04-15	Gan & Lee Pharmaceuticals' Subsidiary Doses First Subject for Phase III of GZR33 Injection Trial; Shares Up 3%	MT
04-09	Gan & Lee Pharmaceuticals - signs exclusive license agreement with JW Pharmaceutical	RE
04-09	Gan & Lee Pharmaceuticals Signs Exclusive License Agreement with JW Pharmaceutical, the Leading South Korean Pharma, to Advance the Global Commercialization of the Innovative GLP-1 Receptor Agonist Bofanglutide	AQ
04-09	Gan & Lee Pharmaceuticals and Jw Pharmaceutical Sign Exclusive License Agreement for Bofanglutide Injection in South Korea	CI
04-08	Gan & Lee Pharmaceuticals Gets Regulatory Approval for Diabetes Combo Drug	MT
04-07	Gan & Lee Pharmaceuticals Doses First Patient in Prostate Cancer Drug Trial	MT
03-31	Gan & Lee Pharmaceuticals' Once-Weekly Basal Insulin GZR4 Injection Meets Primary Endpoints in Two Pivotal Phase 3 Clinical Trials: SUPER-1 and SUPER-2	AQ
03-31	Gan & Lee Pharmaceuticals Announces Once-Weekly Basal Insulin GZR4 Injection Meets Primary Endpoints In Two Pivotal Phase 3 Clinical Trials	CI
03-25	Gan & Lee Pharmaceuticals Gets Drug Trial Approval to Treat Obesity-Related Sleep Apnea	MT
03-03	Gan & Lee Pharmaceuticals Gets Regulatory Nod for Prostate Cancer Drug Trials	MT
01-13	Gan & Lee Pharmaceuticals Appoints Dr. John Wang As Senior Vice President And Chief Strategy Officer, Effective January 12, 2026	CI
01-02	Gan & Lee Pharmaceuticals Removes CFO, Appoints Acting CFO	MT
12-29	Lupin Limited Enters into License, Supply and Distribution Agreement with Gan & Lee Pharmaceuticals for Novel GLP-1 Receptor Agonist, Bofanglutide	CI
11-27	Once-Monthly GLP-1 RA \| Gan & Lee Pharmaceuticals Initiates Phase 3 Clinical Study (GRADUAL-3) of the First Chinese Once-Monthly GLP-1 RA for Weight Management	AQ
11-18	Gan & Lee Pharmaceuticals Europe GmbH Announces Committee for Medicinal Products for Human Use of the European Medicines Agency Recommends the Approval of Insulin Glargine Injection	CI
30/10/25	Gan & Lee Pharmaceuticals. Reports Earnings Results for the Nine Months Ended September 30, 2025	CI
17/10/25	Gan & Lee Pharmaceuticals Appoints Dr. Ting Jia as Chief Medical Officer	CI
29/09/25	Gan & Lee Pharmaceuticals Signs National "Technology Transfer and Supply Agreement" in Brazil to Accelerate Local Insulin Manufacturing	CI
23/09/25	Gan & Lee Pharmaceuticals signs framework agreement	RE
07/09/25	Tranche Update on Gan & Lee Pharmaceuticals.'s Equity Buyback Plan announced on September 6, 2024.	CI
02/09/25	Gan & Lee Pharmaceuticals.'s Equity Buyback announced on September 6, 2024, has expired with 3,540,021 shares, representing 0.6% for CNY 150.07 million	CI